Therefore, considering the high expression of COX-2 in MM tumors, especially in advanced and metastatic stages, targeted therapy using selective COX-2 inhibitory antibodies or NSAIDs may have a potential role in treating melanoma patients, particularly those with malignant types. This evidence concerns the gene PTGS2 and melanoma.